Nektar Therapeutics [NKTR] stock prices are up 5.18% to $58.5 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NKTR shares have gain 6.09% over the last week, with a monthly amount glided 99.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on June 24, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $120 from $6.50. Previously, BTIG Research reaffirmed its Buy rating on June 24, 2025, and elevated its price target to $100. On April 11, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $2 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $6 on March 14, 2025. B. Riley Securities initiated its recommendation with a Buy and recommended $4 as its price target on January 08, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $6.50. In a note dated November 04, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $7 on this stock.
The stock price of Nektar Therapeutics [NKTR] has been fluctuating between $0.43 and $61.15 over the past year. Currently, Wall Street analysts expect the stock to reach $99 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $58.5 at the most recent close of the market. An investor can expect a potential return of 69.23% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
The Nektar Therapeutics [NASDAQ:NKTR] reported sales of 74.93M for trailing twelve months, representing a drop of -52.42%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.34%, Pretax Profit Margin comes in at -1.55%, and Net Profit Margin reading is -1.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -4.93 and Total Capital is -0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.97 points at the first support level, and at 53.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.41, and for the 2nd resistance point, it is at 62.32.
Ratios To Look Out For
It’s worth pointing out that Nektar Therapeutics [NASDAQ:NKTR]’s Current Ratio is 2.61. In addition, the Quick Ratio stands at 2.61 and the Cash Ratio stands at 0.6. Considering the valuation of this stock, the price to sales ratio is 14.85.
Transactions by insiders
Recent insider trading involved ROBIN HOWARD W, President & CEO, that happened on Sep 09 ’25 when 6666.0 shares were sold. Officer, ROBIN HOWARD W completed a deal on Sep 09 ’25 to buy 6666.0 shares. Meanwhile, Chief R&D Officer Zalevsky Jonathan sold 1721.0 shares on Sep 04 ’25.
